Recombinant Yersinia enterocolitica ail/Attachment invasion locus Protein, N-His-SUMO from ProteoGenix; catalogue ARO-P10914; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Recombinant Yersinia enterocolitica ail/Attachment invasion locus Protein, also known as Ail protein, is a key virulence factor in the pathogenesis of Yersinia enterocolitica, a gram-negative bacterium that causes foodborne illness in humans. The Ail protein is a surface-exposed outer membrane protein that plays a crucial role in the attachment and invasion of host cells by Y. enterocolitica. In recent years, the recombinant form of this protein has gained significant attention in the field of biotechnology and medicine due to its potential applications in vaccine development and diagnostic assays.
The Ail protein is a 17 kDa outer membrane protein that is highly conserved among different Yersinia species. It is composed of 159 amino acids and has a predicted β-barrel structure with eight transmembrane β-strands and four extracellular loops. The recombinant form of Ail protein is produced by cloning the full-length gene into an expression vector and expressing it in a suitable host organism, such as Escherichia coli. The recombinant protein retains its native structure and function and can be purified using standard protein purification techniques.
The Ail protein is a multifunctional protein that plays a crucial role in the pathogenesis of Y. enterocolitica. It acts as an adhesin, allowing the bacterium to attach to host cells, particularly intestinal epithelial cells. It also functions as an invasin, facilitating the entry of Y. enterocolitica into host cells by interacting with host cell receptors. In addition, the Ail protein has been shown to have immunomodulatory effects, suppressing the host’s immune response and aiding the survival of the bacterium in the host.
Recombinant Ail protein has several potential applications in the fields of biotechnology and medicine.
The Ail protein has been identified as a potential vaccine candidate for Y. enterocolitica. Recombinant Ail protein can be used to develop subunit vaccines, which are safer and more specific than traditional live attenuated vaccines. Studies have shown that vaccination with recombinant Ail protein can protect mice from lethal Y. enterocolitica infection, making it a promising candidate for the development of a human vaccine.
The Ail protein has been shown to be highly immunogenic, making it a potential antigen for the development of diagnostic assays for Y. enterocolitica. Recombinant Ail protein can be used in serological assays, such as ELISA, to detect the presence of antibodies against Y. enterocolitica in patient samples. It can also be used in lateral flow assays for rapid and point-of-care diagnosis of Y. enterocolitica infection.
The Ail protein has been shown to have immunomodulatory effects, making it a potential therapeutic target for the treatment of inflammatory and autoimmune diseases. Recombinant Ail protein can be used to develop immunomodulatory therapies that target specific immune cells or pathways, offering a more targeted and effective treatment option.
Further research is needed to fully understand the structure and function of the Ail protein and its potential applications. Studies are ongoing to determine the effectiveness of recombinant Ail protein as a vaccine candidate and its potential as a diagnostic and therapeutic tool. Additionally, efforts are being made to develop more efficient and cost-effective methods for the production of recombinant Ail protein.
The Recombinant Yersinia enterocolitica ail/Attachment invasion locus Protein is a key virulence factor in Y.
ProteoGenix catalogue number ARO-P10914. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 29.64 kDa; Fragment: Ala24-Phe178; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
